跳转至内容
Merck
CN

MAB5466

Anti-Bestrophin Antibody

Chemicon®, from mouse

别名:

Anti-Anti-ARB, Anti-Anti-BEST, Anti-Anti-BMD, Anti-Anti-Best1V1Delta2, Anti-Anti-RP50, Anti-Anti-TU15B, Anti-Anti-VMD2

登录 查看公司和协议定价

选择尺寸


关于此项目

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

mouse

质量水平

偶联物

unconjugated

抗体形式

purified immunoglobulin

抗体产品类型

primary antibodies

克隆

monoclonal

种属反应性

monkey, pig, mouse, bovine, human

制造商/商品名称

Chemicon®

技术

immunohistochemistry: suitable
western blot: suitable

同位素/亚型

IgG

NCBI登记号

UniProt登记号

运输

dry ice

靶向翻译后修饰

unmodified

基因信息

human ... BEST1(7439)

免疫原

Recombinant human bestrophin protein.

应用

Detect Bestrophin using this Anti-Bestrophin Antibody validated for use in WB, IH.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Western blot: 5 μg/mL of this antibody detected Bestrophin in bovine retina cell lysate.

Immunohistochemistry (Paraffin) Analysis: A 1:20 dilution from a representative lot detected Bestrophin in mouse retina tissue sections.

Optimal working dilutions must be determined by end user.

生化/生理作用

Reacts with bestrophin.

外形

Format: Purified
Purified immunoglobulin. Liquid in PBS containing 0.08% sodium azide.

制备说明

Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.

其他说明

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

10 - Combustible liquids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Altered zinc homeostasis in a primary cell culture model of the retinal pigment epithelium.
??lvarez-Barrios, et al.
Frontiers in nutrition, 10, 1124987-1124987 (2023)
Sandra Petrus-Reurer et al.
Stem cells translational medicine, 9(8), 936-953 (2020-04-23)
As pluripotent stem cell (PSC)-based reparative cell therapies are reaching the bedside, there is a growing need for the standardization of studies concerning safety of the derived products. Clinical trials using these promising strategies are in development, and treatment for
Teisha J Rowland et al.
Journal of tissue engineering and regenerative medicine, 7(8), 642-653 (2012-04-20)
A potential application of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) is the generation of retinal pigmented epithelium (RPE) to treat age-related macular degeneration (AMD), a common but incurable retinal disease. RPE cells derived from hESCs
Alvaro Plaza Reyes et al.
Nature communications, 11(1), 1609-1609 (2020-04-02)
In vitro differentiation of human pluripotent stem cells into functional retinal pigment epithelial (RPE) cells provides a potentially unlimited source for cell based reparative therapy of age-related macular degeneration. Although the inherent pigmentation of the RPE cells have been useful
Divya Sinha et al.
American journal of human genetics, 107(2), 278-292 (2020-07-25)
Dominantly inherited disorders are not typically considered to be therapeutic candidates for gene augmentation. Here, we utilized induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) to test the potential of gene augmentation to treat Best disease, a dominant macular dystrophy

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持